Lobeglitazone clinical trials
Also written CKD-501.
How each study uses lobeglitazone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
28 studies that test it; most in 2018 (4)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 2 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 4 |
| 2020 | 2 |
| 2021 | 1 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 25 · Other 3
Chong Kun Dang Pharmaceutical (25) · Seoul National University Bundang Hospital (2) · Pusan National University Hospital (1)
Often tested with
Tested in the same studies.
Sitagliptin (1) · Dapagliflozin (1) · D759 (1) · D745 (1) · Warfarin (1) · Pioglitazone (1) · Empagliflozin (1)
Studies
Open first, then newest update. How each study uses lobeglitazone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 28
- Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy VolunteersCompletedPhase 1Chong Kun Dang PharmaceuticalNCT07304700Written as CKD-501, D744, D150
- Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy VolunteersCompletedPhase 1Chong Kun Dang PharmaceuticalNCT07304687Written as CKD-501, D745, D150
- Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy VolunteersCompletedPhase 1Chong Kun Dang PharmaceuticalNCT07304726Written as CKD-501, D745, D150
- Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg DuvieCompletedPhase 4Pusan National University HospitalNCT03770052Written as duvie
- Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination TherapyCompletedPhase 4Seoul National University Bundang HospitalNCT02338921Written as Lobeglitazone
- Efficacy and Safety of CKD-501 Added to D150 Plus D745 10mg Therapy in Patients With Type 2 DiabetesCompletedPhase 3Chong Kun Dang PharmaceuticalNCT03739125Written as CKD-501 0.5mg
- Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes ManagementStatus unknownPhase 4Seoul National University Bundang HospitalNCT02315287Written as Lobeglitazone
- Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393Status unknownPhase 1Chong Kun Dang PharmaceuticalNCT04706286Written as CKD-501, D759, D150
- A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393)CompletedPhase 1Chong Kun Dang PharmaceuticalNCT04431687Written as CKD 501
- A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D745 and D150CompletedPhase 1Chong Kun Dang PharmaceuticalNCT04334213Written as CKD-501
- Clinical Trial to Evaluate the Drug Drug Interaction of CKD-501 and D308CompletedPhase 1Chong Kun Dang PharmaceuticalNCT03616392Written as D308, CKD-501
- The Efficacy and Safety of CKD-501 Added to D150 Plus D759 Therapy in Patients With Type 2 DiabetesStatus unknownPhase 3Chong Kun Dang PharmaceuticalNCT03641352Written as CKD-501 0.5mg
- Efficacy and Safety of CKD-501 Added to D150 Plus D745 25mg Therapy in Patients With Type 2 DiabetesStatus unknownPhase 3Chong Kun Dang PharmaceuticalNCT03627182Written as CKD-501 0.5mg
- Comparative Evaluation of Pharmacokinetics After CKD-501 Between Renal Impaired and Normal Renal Function SubjectsCompletedPhase 1Chong Kun Dang PharmaceuticalNCT02007941Written as CKD-501
- Evaluate the Drug-drugs Interaction Between Lobeglitazone and EmpagliflozinStatus unknownPhase 1Chong Kun Dang PharmaceuticalNCT02854748Written as Lobeglitazone 0.5mg
- CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1)CompletedPhase 1Chong Kun Dang PharmaceuticalNCT02824874Written as Duvie Tab. 0.5mg
- A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic FunctionCompletedPhase 1Chong Kun Dang PharmaceuticalNCT02005744Written as CKD-501
- Investigate the Effect of Food on the Pharmacokinetic Characteristics of CKD-395 in Healthy Male VolunteersCompletedPhase 1Chong Kun Dang PharmaceuticalNCT02648854Written as CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T
- A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male VolunteersCompletedPhase 1Chong Kun Dang PharmaceuticalNCT02565368Written as CKD-395 0.5/1000mg
- Drug-drug Interaction Study(Lobeglitazone, Warfarin)CompletedPhase 1Chong Kun Dang PharmaceuticalNCT02002611Written as Lobeglitazone
See all 28 studies that test lobeglitazone →
Given beside what is tested · 8 — lobeglitazone is usual care or a partner of the new treatment
- Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029CompletedPhase 1Chong Kun Dang PharmaceuticalNCT05897216Written as CKD-501, D745, D150, D029
- Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150CompletedPhase 1Chong Kun Dang PharmaceuticalNCT05816759Written as CKD-501, D744, D150
- Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393CompletedPhase 1Chong Kun Dang PharmaceuticalNCT05113693Written as CKD-501, D759, H053
- A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed ConditionsCompletedPhase 1Chong Kun Dang PharmaceuticalNCT05347576Written as CKD-501, D759, D150, D029
- Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mgCompletedPhase 1Chong Kun Dang PharmaceuticalNCT04869800Written as CKD-501, D745
- A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-383.CompletedPhase 1Chong Kun Dang PharmaceuticalNCT04810676Written as CKD-501, D745, D150
- Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy SubjectsCompletedPhase 1Chong Kun Dang PharmaceuticalNCT04260438Written as CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T
- A Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-396Status unknownPhase 1Chong Kun Dang PharmaceuticalNCT04246190Written as CKD-501 and D759
As the comparator · 1 — what is tested is compared with lobeglitazone
Codes
What other systems call lobeglitazone · ClinicalTrials.gg INT005553
- MeSH (NLM) C546215lobeglitazoneOne source NLM
- UNII (FDA) MY89F08K5DLOBEGLITAZONEConfirmed FDA, NLM, Wikidata
- Wikidata Q18350076(RS)-lobeglitazoneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C91021LobeglitazoneOne source FDA
- DrugBank DB09198One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C546215 | lobeglitazone | One source NLM |
| UNII (FDA) | MY89F08K5D | LOBEGLITAZONE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q18350076 | (RS)-lobeglitazone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C91021 | Lobeglitazone | One source FDA |
| DrugBank | DB09198 | — | One source Wikidata |
Also registered as lobeglitazone sulfate (UNII 95C712E83P).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.